Search

A retrospective study of 20 patients between March 2015 and September 2021 found that individuals, mostly men, developed thrombocytopenia while being treated with tirofiban for various conditions like acute myocardial infarction and cerebral infarction. The patients experienced adverse reactions to tirofiban, leading to low platelet counts, with some requiring glucocorticoids and platelet transfusions. While most patients recovered, unfortunately, two individuals died due to respiratory and cardiac arrest. The study highlights the importance of monitoring patients for potential adverse effects of tirofiban during treatment. [Extracted from the article]

A retrospective study involving 405 patients who underwent allogeneic haematopoietic stem cell transplantation revealed 19 cases of lack of drug efficacy and treatment failure with aciclovir and ganciclovir for cytomegalovirus prophylaxis. Despite initial treatment, patients developed CMV pneumonia, leading to varied treatment regimens including foscarnet, immune-globulin, and cytotoxic-T-lymphocytes, with some cases resulting in complete resolution of pneumonia while others ended in death due to treatment failure. The study highlights the complexities and challenges in managing CMV infections post-transplantation, emphasizing the need for tailored treatment approaches. [Extracted from the article]

A retrospective study described 10 patients who experienced various toxicities and lack of efficacy while being treated for tuberculosis (TB) with ethambutol, isoniazid, pyrazinamide, and rifampicin. The toxicities included acute interstitial nephritis, crescentic glomerulonephritis, thrombocytopenic purpura, acute tubular injury with intravascular hemolysis, DRESS, acute pancreatitis, cerebellitis, acute gout, and immune reconstitution inflammatory syndrome (IRIS). One patient also developed accelerated hypertension with posterior reversible encephalopathy syndrome (PRES) due to a drug interaction between labetalol and rifampicin. Another patient experienced lack of efficacy with furosemide and sodium-chloride for hypercalcemia. The patients' symptoms and conditions improved after discontinuing the implicated drugs or making appropriate changes to the treatment regimen. [Extracted from the article]

A retrospective study was conducted on 19 patients who developed thyroiditis or Grave's disease after receiving the tozinameran COVID-19 vaccine. The patients ranged in age from 22 to 72 years and included both men and women. The study described the cases of each patient, including their medical history and the progression of their condition after vaccination. Some patients experienced complete remission of their condition with treatment, while others continued to have active disease. In a few cases, patients developed thyroiditis as a result of the vaccine. Overall, the study provides insight into the potential side effects of the tozinameran vaccine on the thyroid. [Extracted from the article]

A retrospective study described 11 patients who developed various vestibular disorders and sudden sensorineural hearing loss (SSNHL) following immunization with COVID-19 vaccines. The patients experienced symptoms such as dizziness, vertigo, and nystagmus after receiving vaccines such as AZD-1222 (AstraZeneca), tozinameran (Pfizer-BioNTech), and elasomeran (Moderna). The study attributed these adverse effects to the vaccines and noted that vestibular rehabilitation and other treatments led to improvements in the patients' conditions. [Extracted from the article]

A retrospective study of 60 patients conducted between January 2017 and June 2019 reported a case of a patient who developed acute kidney injury (AKI) during treatment with vancomycin. The patient initially received intermittent IV vancomycin but switched to a continuous infusion after developing AKI, leading to a slow resolution of the condition. The specific details regarding the patient's age, sex, dosage, indication, and duration of treatment to reaction onset were not provided in the study. [Extracted from the article]

Two case reports were presented in a retrospective study from 2002 to 2022, detailing the development of polycythaemia in two women receiving siltuximab treatment for Castleman disease. The first woman, aged 46, experienced polycythaemia after the first dose of siltuximab, which was successfully managed with phlebotomy. The second woman, aged 32, also developed polycythaemia after siltuximab infusion, and despite receiving multiple infusions, she ultimately passed away due to lack of efficacy in treating her condition. [Extracted from the article]

A retrospective study involving 81 children found one case of cardiac dysfunction in a child receiving selumetinib for cancer treatment. The specific details of the patient's age, sex, route of administration, dosage, duration of treatment, and outcome were not provided in the study. The child was diagnosed with cancer, started receiving selumetinib, and developed cardiac dysfunction as a side effect of the treatment. [Extracted from the article]

A retrospective study involving 66 patients treated with remdesivir for COVID-19 between February 2022 and September 2023 found that 11 patients developed liver enzyme elevation. The patients experienced varying degrees of elevation in AST and ALT levels, with some requiring discontinuation of remdesivir therapy. While most patients showed improvement in liver enzyme levels after stopping treatment, a few continued to experience elevated levels. [Extracted from the article]

A retrospective study involving 157 patients from July 2022 to February 2023 reported three cases of adverse reactions to polyvalent-snake-antivenin treatment for snakebites. Patients developed symptoms such as urticaria, itching, tachycardia, hypotension, cough, fever, and rigor. Treatment with adrenaline, steroids, and antihistamines led to recovery in all cases. The study did not specify the ages or genders of the patients. [Extracted from the article]

A retrospective study of 211 female patients between July 2019 and July 2021 found cases of chest tightness and hypokalaemia in pregnant women receiving ritodrine or phloroglucinol for miscarriage prevention. Three patients received IV ritodrine or phloroglucinol, with two developing chest tightness and hypokalaemia due to ritodrine and one experiencing chest tightness from phloroglucinol. Symptoms resolved with hospital treatment, but pregnancy outcomes were not reported. [Extracted from the article]

A retrospective study described two patients with stage II conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma who experienced adverse effects during treatment. The first patient, a 49-year-old woman, developed numbness of hands and fingers, abdominal pain, and pancytopenia while receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. The second patient, a 36-year-old woman, experienced fever and general malaise with rituximab monotherapy. Both patients received unspecified symptomatic therapy and showed improvement in their adverse effects. [Extracted from the article]

A retrospective study of 23 children with acute lymphoblastic leukemia (ALL) found that a child developed an infection while undergoing treatment with multiple drugs, including asparaginase, cyclophosphamide, and vincristine. Despite receiving prophylaxis for pneumonia, the child required admission to the intensive care unit due to the infection. The development of the infection was attributed to the combination of chemotherapy drugs used in the treatment protocol. [Extracted from the article]

A retrospective study described 62 cases of individuals, aged 17-76, who died following drug abuse of various substances such as caffeine, amfetamine, metamfetamine, fentanyl, etizolam, and others. Postmortem blood concentrations confirmed that the individuals died due to drug abuse of these substances, along with multiple concomitant drugs and illicit substances. All 62 patients were found dead, highlighting the serious consequences of drug abuse. [Extracted from the article]

A retrospective study in India involving 10 patients with sporadic inclusion body myositis (sIBM) reported a case of lack of efficacy in a patient receiving methotrexate, rituximab, and steroids for treatment. The patient, who also had rheumatoid arthritis, remained bed-bound despite the treatment, indicating the ineffectiveness of the medications. This case highlights the challenges in managing sIBM and the need for further research into more effective treatment options. [Extracted from the article]

A case report published in Reactions Weekly describes a 53-year-old patient who developed contrast-induced nephropathy after receiving iohexol as a contrast media during coronary angiography at Jena University Hospital. The patient's outcome and specific details such as dosage, route, time to reaction onset, and outcome were not provided in the report. This retrospective study highlights the potential risks associated with contrast media use in medical procedures. [Extracted from the article]

A retrospective study of 217 patients with type 2 diabetes mellitus (T2DM) found five cases of fasting hypoglycemia during treatment with insulin-degludec. The patients, ranging from 27 to 79 years old, developed hypoglycemia while on insulin-degludec therapy, with some also having other medical conditions like hypopituitarism and chronic kidney disease. The study did not specify the routes, dosages, durations of treatments, or outcomes for these cases. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA retrospective study conducted between January 2019 and December 2022 involving 170 patients, et al. patient [age and sex not stated] was described, who exhibited lack of efficacy during treatment withimatinib for chronic myeloid leukaemia. The patient, who had chronic myeloid leukaemia, had received imatinib 400mg once daily. However, the patient lost major molecular response (lack of efficacy). [Extracted from the article]

A retrospective study from January 2017 to June 2023 examined 15 patients who developed anaphylaxis, urticaria, or angioedema while being treated for iron deficiency anaemia with ferrioxypolymaltose, iron-sucrose, or ferrous-glycine-sulfate. The patients received iron preparations such as ferrioxypolymaltose, iron-sucrose, or ferrous-glycine-sulfate, and two patients experienced anaphylaxis while one had urticaria and angioedema. Following the reactions, the patients underwent desensitisation with ferric carboxymaltose. [Extracted from the article]

A retrospective study involving 21 fetus patients treated for fetal supraventricular tachycardia found a case where digoxin was ineffective. The mother of the fetus received digoxin during pregnancy, but it did not have the desired effect on the fetal condition. As a result, the mother switched to sotalol as an alternative treatment. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a single-center, retrospective study of 9 patients with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), et al. patients [ages and sexes not stated] were described, who exhibited treatment failure during treatment with cyclophosphamide (1 patient) and interferon-beta-1a (1 patient) for CLIPPERS [routes and dosages not stated]. [Extracted from the article]

A retrospective study reported a case of a heart transplant patient diagnosed with COVID-19 who received treatment with remdesivir and off-label convalescent-anti-SARS-CoV-2-plasma. Despite additional treatments like monoclonal antibodies, oxygen, steroids, and antibiotics, the patient did not respond to the therapy and unfortunately passed away. This case highlights the lack of efficacy of remdesivir and convalescent-anti-SARS-CoV-2-plasma in this particular patient. [Extracted from the article]

A retrospective study involving 341 patients with lumbar disc herniation (LDH) found three cases where patients developed infection, drug eruption, or vertebral body fracture during treatment with condoliase and sodium-chloride. The patients received intradiscal condoliase dissolved in sodium-chloride for LDH treatment, leading to these adverse reactions. One patient developed an infection, another experienced a drug eruption, and a third suffered a vertebral body fracture adjacent to the treated intervertebral disc. [Extracted from the article]

A retrospective study from 2016 to 2020 involving 95 patients highlighted a case of an 81-year-old woman with ocular chronic graft-versus-host disease (GVHD) who did not respond to treatment with ciclosporin and tacrolimus. Following allogeneic haematopoietic stem cell transplantation, the woman developed ocular chronic GVHD affecting her lids, conjunctiva, and cornea. Despite receiving ciclosporin and tacrolimus, these medications did not alleviate the inflammatory activity, leading to the initiation of prolonged steroid therapy. [Extracted from the article]

Two case reports were presented in a multicenter retrospective study involving 106 patients between April 2019 and January 2023, where two men, aged 95 and 86, developed immune thrombocytopenia or autoimmune hepatitis while being treated with cemiplimab for cutaneous squamous cell carcinoma. The men received IV cemiplimab 350mg every 3 weeks and one of them had chronic lymphocytic leukemia. Tragically, both men passed away due to complications from immune thrombocytopenia or autoimmune hepatitis. [Extracted from the article]

A retrospective study involving 279 patients examined data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and described a female patient with breast cancer who developed gastrointestinal haemorrhage during treatment with capecitabine. The specific details of the treatment, including route, dosage, outcome, and duration of treatment to reaction onset, were not provided in the report. The case highlights a potential adverse effect of capecitabine in cancer treatment. [Extracted from the article]

A single-center retrospective study involving 36 patients between May 2022 and September 2023 reported a case of an adult patient with psoriatic arthritis who showed lack of efficacy while being treated with bimekizumab. The patient received bimekizumab at a dosage of 320mg every 4 weeks, but experienced exacerbation of psoriatic arthritis, indicating lack of effectiveness. [Extracted from the article]

A retrospective study involving 115 patients who underwent venom immunotherapy between 1995 and 2018 reported four cases of lack of efficacy in bee-venom-allergy-immunotherapy or wasp-venom-allergy-immunotherapy. Despite receiving immunotherapy, the patients experienced systemic allergic reactions after field stings, indicating a lack of effectiveness in preventing such reactions. The study highlights the challenges in managing bee and wasp venom allergies through immunotherapy. [Extracted from the article]

A retrospective study involving 184 patients between April 2010 and August 2021 found that 12 patients developed pancreatitis while being treated with asparaginase for cancer. All patients received chemotherapy regimens that included asparaginase, leading to pancreatitis. Octreotide was given prophylactically before subsequent asparaginase administrations, resulting in no relapse for eight patients and successful treatment for four patients with relapsed pancreatitis. [Extracted from the article]

A retrospective study of 54 patients with neovascular age-related macular degeneration (nAMD) found that a 76-year-old man showed lack of efficacy while being treated with aflibercept and other vascular endothelial growth factor-A inhibitors. Despite receiving multiple injections of aflibercept and other anti-VEGF treatments, the man continued to have persistent macular fluid, indicating treatment ineffectiveness. After switching to faricumab, his central macular thickness decreased, visual acuity improved, and intraretinal macular edema was reduced. [Extracted from the article]

A study published in the Journal of International Medical Research found that treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy does not increase the risk of COVID-19 infection in patients with non-small cell lung cancer (NSCLC). The retrospective study conducted in China showed that over an 18-month follow-up period, 80.5% of patients developed COVID-19 infections, with 12.6% requiring hospitalization and 1.4% dying due to COVID. The study also found that rates of COVID infection and hospitalization were lower in patients who had received COVID-19 vaccination, had a higher body mass index, and had no comorbidities. [Extracted from the article]

A retrospective study published in Clinical Drug Investigation found that Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as abemaciclib, palbociclib, and ribociclib, may increase the risk of neurological and psychiatric adverse events (AEs). Data from the US FDA Adverse Event Reporting System (FAERS) showed positive signals for AEs like spinal cord herniation, aversion, and cerebral microangiopathy in patients aged 65-85 years. The study emphasized the importance of close monitoring due to the severity and early onset of these AEs associated with CDK4/6 inhibitors. [Extracted from the article]

In a retrospective study of patients with relapsed or refractory primary central nervous system lymphoma (PCNSL), two individuals developed eruptions while being treated with tirabrutinib. The patients, whose ages and genders were not specified, experienced tirabrutinib-related eruptions during their treatment. As a result, one patient had their tirabrutinib dosage reduced to 320mg, while the other patient discontinued the medication altogether. [Extracted from the article]

A retrospective study of 257 patients receiving temozolomide for malignant glioma reported four cases of adverse reactions: one patient developed aplastic anaemia, another thrombocytopenia, and two patients experienced neutropenia. These patients required hospitalization and medical interventions such as blood transfusions and platelet transfusions. The study did not provide specific details on the ages, genders, dosages, or outcomes of the patients. [Extracted from the article]

A retrospective study from October 2016 to March 2019 examined 12 patients with pulmonary hypertension associated with lung disease (PH-LD) who showed lack of efficacy while being treated with selexipag. Patients with PH-LD, including those with chronic obstructive pulmonary disease and interstitial lung disease related to systemic sclerosis, did not respond to selexipag treatment and experienced adverse outcomes, including death. The study highlights the challenges in managing PH-LD with selexipag and the need for further research in this area. [Extracted from the article]

A retrospective study of 23 patients with HER2-positive advanced nonsmall cell lung cancer in China found two cases of adverse reactions to off-label use of pyrotinib. One patient developed grade 4 leukopenia, which was well controlled, while another experienced grade 3 diarrhea, leading to discontinuation of pyrotinib treatment. The study did not provide details on the ages, sexes, dosages, or durations of treatments for these patients. [Extracted from the article]

A retrospective study involving 20 patients between January 2018 and December 2019 reported a case of a patient with metastatic non-small cell lung cancer who developed grade III pneumonitis while being treated with pembrolizumab. The patient received IV pembrolizumab infusion but had to stop treatment due to the pneumonitis, and was subsequently started on corticosteroid therapy. The specific details of the patient's age, sex, duration of treatment to reaction onset, and outcome were not provided in the report. [Extracted from the article]

A case report published in Reactions Weekly describes an elderly patient with esophageal squamous cell carcinoma who developed grade 5 pneumonitis during paclitaxel therapy. The patient had a history of ESCC and received chemotherapy with paclitaxel, but unfortunately died due to pneumonitis after completing the treatment. This retrospective study highlights the serious nature of adverse events associated with paclitaxel in cancer treatment. [Extracted from the article]

A retrospective study conducted in Tunisia between 2000 and 2019 reported seven cases of acute generalised exanthematous pustulosis (AGEP) in patients receiving various medications, including metronidazole, spiramycin, ibuprofen, piroxicam, lornoxicam, lamotrigine, phenytoin, and allergen-immunotherapy. Some patients developed AGEP after receiving ibuprofen, piroxicam, and lornoxicam, while others developed it after antibiotics therapy or antiepileptic treatment. Skin patch tests confirmed positive reactions to piroxicam and lornoxicam in patients who received ibuprofen, piroxicam, and lornoxicam. [Extracted from the article]

The article presents a retrospective study of 12 patients, aged 16.0-49.5 months, who developed various toxicities during treatment for myeloid leukemia associated with Down syndrome. The patients experienced adverse effects such as leucopenia, neutropenia, anaemia, thrombocytopenia, infections, and organ dysfunctions while receiving medications like azacitidine, methotrexate, hydrocortisone, and cytarabine. Despite treatment, some patients did not respond effectively to the medications and ultimately succumbed to the disease, highlighting the challenges in managing leukemia in this population. [Extracted from the article]

A retrospective study examined 61 patients who underwent heart transplantation between 2008 and 2019, with some developing post-transplant lymphoproliferative disorder, perianal ulcers, chronic cytomegalovirus replication, leukocytopenia, or lack of efficacy during treatment with various drugs. Some patients experienced serious complications, including death due to primary graft failure or aspergillosis. Treatment adjustments were made for patients experiencing adverse reactions, such as switching medications to manage side effects like chronic CMV replication or resolving perianal ulcers. The study highlights the complexities and challenges of managing drug toxicities and lack of efficacy in transplant patients. [Extracted from the article]

A retrospective study described seven patients with cobalamin C (Cb1C) disease who showed lack of efficacy while being treated with betaine, folinic-acid, hydroxocobalamin, and levocarnitine. Patients exhibited symptoms such as poor weight gain, cardiomyopathy, seizures, hypotonia, and feeding difficulties despite receiving treatment. The study highlighted the challenges in managing Cb1C disease and the need for further research to improve treatment outcomes for affected individuals. [Extracted from the article]

A retrospective study of 13 patients between 2015 and 2021 described cases of lack of efficacy with anticoagulant drugs like acenocoumarol, heparin, rivaroxaban, or argatroban for primary aortic mural thrombus, as well as instances of heparin-induced thrombocytopenia. Patients, aged 36-68, had various medical histories and diagnoses, with some experiencing recurrences despite treatment and others developing serious complications like mesenteric and limb ischemia, renal infarcts, and death. [Extracted from the article]

A nonrandomized single-center retrospective study involving 63 patients reported two cases of individuals developing cytomegalovirus (CMV) infections and COVID infections during immunosuppression treatment post-heart transplant. Patient 1 received antithymocyte-globulin, methylprednisolone, prednisone, mycophenolate-mofetil, and tacrolimus, leading to CMV infections. Patient 2 received basiliximab, methylprednisolone, prednisone, mycophenolate-mofetil, and tacrolimus, resulting in COVID infections. The outcomes and durations of treatment to reaction onset were not specified in the study. [Extracted from the article]

Two case reports from a retrospective study between 2011 and 2021 describe two men, aged 67 and 64, who developed blastomycosis while undergoing immunosuppressant drug therapy. The 67-year-old man also showed lack of efficacy with isavuconazole treatment for histoplasmosis and blastomycosis, ultimately leading to his death. The 64-year-old man, who had undergone heart transplantation, was successfully treated with itraconazole for blastomycosis. [Extracted from the article]

A retrospective study of 253 patients conducted between March 2020 and April 2022 reported a case of a pregnant woman with COVID-19 who received off-label treatment with methylprednisolone but showed no improvement. Despite receiving 32mg of methylprednisolone daily, the woman did not respond to the treatment and unfortunately passed away. The study highlights the lack of efficacy of methylprednisolone in this particular case, emphasizing the need for further research on its use during pregnancy for COVID-19. [Extracted from the article]

A retrospective study described three cases of acute phase reaction (APR) in patients aged 7.5-12.5 years receiving zoledronic-acid, tocilizumab, or methotrexate for Duchenne muscular dystrophy or systemic juvenile idiopathic arthritis. One patient with systemic JIA developed APR after receiving zoledronic-acid, tocilizumab, and methotrexate, leading to hospitalization for 10 days. Two patients with DMD also developed APR after zoledronic-acid infusion, resulting in hospitalization and treatment with fluids. [Extracted from the article]